🇺🇸 FDA
Patent

US 12338249

Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea

granted A61PA61P15/00A61P35/00

Quick answer

US patent 12338249 (Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea) held by Takeda Pharmaceutical Company Limited expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P15/00, A61P35/00